Refine
Document Type
- Article (12)
Language
- English (12)
Has Fulltext
- yes (12)
Is part of the Bibliography
- no (12)
Keywords
- - (10)
- aging (4)
- lipidomics (3)
- caveolae (2)
- erythrocytes (2)
- fatty acids (2)
- hemodialysis (2)
- inflammation (2)
- perivascular adipose tissue (2)
- ADPKD (1)
- Alzheimer’s disease (1)
- Assessment (1)
- CKD (1)
- Chronic kidney disease (1)
- Cognition (1)
- K (1)
- Mobility (1)
- NZO mice (1)
- Nutrition (1)
- Physical function (1)
- RNA sequencing (1)
- SH045 (1)
- TRPC6 (1)
- T‐type calcium channels (1)
- UUO (1)
- alamandine (1)
- angiotensin II type 1a receptor (1)
- anti-inflammatory strategies (1)
- arterial smooth muscle (1)
- arterio-venous (1)
- autosomal-dominant polycystic kidney disease (1)
- biased ligands (1)
- biotransformation (1)
- calcium sparks (1)
- calorie restriction (1)
- calorimetry (1)
- chronic kidney disease (1)
- chronic kidney disease (CKD) (1)
- dialysis (1)
- eating behaviour (1)
- eicosanoids (1)
- erythrocyte (1)
- everolimus (1)
- exercise (1)
- fibrosis (1)
- hypertension (1)
- inflammasome (1)
- insulin resistance (1)
- mesenteric artery (1)
- metaflammasome (1)
- microdialysis (1)
- myogenic vasoconstriction (1)
- nitric oxide (1)
- oxylipins (1)
- renal denervation (1)
- ryanodine receptors (1)
- soluble guanylyl cyclase (1)
- soluble guanylyl cyclase activator (1)
- transcriptome (1)
- vascular smooth muscle (1)
Institute
Publisher
- MDPI (4)
- Frontiers Media S.A. (3)
- Wiley (3)
- S. Karger AG (1)
Abstract
Fatty acid products derived from cytochromes P450 (CYP) monooxygenase and lipoxygenase (LOX)/CYP ω/(ω‐1)‐hydroxylase pathways are a superclass of lipid mediators with potent bioactivities. Whether or not the chronic kidney disease (CKD) and hemodialysis treatments performed on end‐stage renal disease (ESRD) patients affect RBC epoxy fatty acids profiles remains unknown. Measuring the products solely in plasma is suboptimal. Since such determinations invariably ignore red blood cells (RBCs) that make up 3 kg of the circulating blood. RBCs are potential reservoirs for epoxy fatty acids that regulate cardiovascular function. We studied 15 healthy persons and 15 ESRD patients undergoing regular hemodialysis treatments. We measured epoxides derived from CYP monooxygenase and metabolites derived from LOX/CYP ω/(ω‐1)‐hydroxylase pathways in RBCs by LC–MS/MS tandem mass spectrometry. Our data demonstrate that various CYP epoxides and LOX/CYP ω/(ω‐1)‐hydroxylase products are increased in RBCs of ESRD patients, compared to control subjects, including dihydroxyeicosatrienoic acids (DHETs), epoxyeicosatetraenoic acids (EEQs), dihydroxydocosapentaenoic acids (DiHDPAs), and hydroxyeicosatetraenoic acids (HETEs). Hemodialysis treatment did not affect the majority of those metabolites. Nevertheless, we detected more pronounced changes in free metabolite levels in RBCs after dialysis, as compared with the total RBC compartment. These findings indicate that free RBC eicosanoids should be considered more dynamic or vulnerable in CKD.
Background: Mild-to-moderate chronic kidney disease (CKD G3a) is prevalent in older adults. Substantial evidence suggests that individuals with advanced CKD face a high risk for common geriatric conditions, like functional impairment and cognitive decline, whereas the relationships between mild-to-moderate CKD and functional impairment and cognitive decline, but also poor nutritional status and mood disorders, are still unclear. Objective: The aim of this study was to explore associations between mild-to-moderate CKD and impairments in the core domains of geriatric assessment (GA) in a large cohort of community-dwelling older adults. Methods: This was a cross-sectional analysis of 1,476 participants of the Berlin Aging Study II. Study participants were stratified as to presence or absence of CKD G3a (estimated glomerular filtration rate [eGFR] 45-59 mL/min/1.73 m<sup>2</sup> vs. eGFR ≥60 mL/min/1.73 m<sup>2</sup>). GA comprised the following instruments: the Activities of Daily Living Scale (ADL), the Timed up and Go (TUG), the Tinetti test (Tinetti), the Mini-Mental-State Examination (MMSE), the Geriatric Depression Scale (GDS), and the Mini Nutritional Assessment (MNA). We used logistic regression models to estimate multivariable-adjusted associations between CKD G3a and impairments in the respective domains. Results: A total of 282 subjects with mild-to-moderate CKD (CKD G3a) were identified (19.1%). Overall, the prevalence of impairments identified was higher among subjects with compared to without CKD G3a (21 vs. 15.9%, p = 0.043). In multivariable-adjusted models, CKD G3a was consistently associated with increased odds of an impaired gait performance as to the TUG (adjusted odds ratio 2.06, 95% CI 1.04-4.09). In contrast, on average, individuals with and without CKD G3a did not differ as to their results in the MMSE, the ADL, the MNA, and the GDS. Conclusion: GA identified impairments in 21 versus 15.9% of older adults with and without mild-to-moderate CKD, respectively. However, except for an increased likelihood of impaired gait performance (TUG) with mild-to-moderate CKD, we did not find independent associations between mild-to-moderate CKD and geriatric conditions.